Biological E. Limited — Antitoxin Exporter Profile
Indian Pharmaceutical Exporter · #4 for Antitoxin · $1.1M export value · DGFT Verified
Biological E. Limited is the #4 Indian exporter of Antitoxin with $1.1M in export value and 20 verified shipments. Biological E. Limited holds a 6.0% market share in Antitoxin exports across 10 countries. The company exports 5 pharmaceutical products worth $80.3M across 3 therapeutic categories.
Biological E. Limited — Antitoxin Export Profile: Buyers & Destinations
Where Does Biological E. Limited Export Antitoxin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED ARAB EMIRATES | $171.9K | 4 | 33.7% |
| FRANCE | $154.1K | 4 | 30.2% |
| NIGERIA | $100.0K | 4 | 19.6% |
| MAURITANIA | $50.0K | 1 | 9.8% |
| MADAGASCAR | $12.6K | 1 | 2.5% |
| UGANDA | $9.3K | 2 | 1.8% |
| SOMALIA | $4.5K | 1 | 0.9% |
| GUINEA | $4.2K | 1 | 0.8% |
| RWANDA | $3.5K | 1 | 0.7% |
| UNITED KINGDOM | $32 | 2 | 0.0% |
Biological E. Limited exports Antitoxin to 12 countries. The largest destination is UNITED ARAB EMIRATES accounting for 33.7% of Biological E. Limited's Antitoxin shipments, followed by FRANCE (30.2%) and NIGERIA (19.6%). These destinations reflect Biological E. Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Antitoxin from Biological E. Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| WORLD HEALTH ORGANIZATION | UNITED ARAB EMIRATES | $171.9K | 4 |
| MSF LOG-BDX SITE MERIGNAC, | FRANCE | $127.8K | 3 |
| NCDC NIGERIA CENTRE FOR DISEASE | NIGERIA | $50.0K | 1 |
| NCDC (NIGERIA CENTRE FOR DISEASE | NIGERIA | $50.0K | 1 |
| CENTRALE D ACHAT DES MEDICAMENTS | MAURITANIA | $50.0K | 1 |
| MSF LOG-BDX SITE MERIGNAC | FRANCE | $26.2K | 1 |
| SALAMA | MADAGASCAR | $12.6K | 1 |
| GITTOES PHARMACEUTICALS LTD., | UGANDA | $5.6K | 1 |
| WEHEHLIYE PHARMACEUTICALS IMPORT CO | SOMALIA | $4.5K | 1 |
| AFRICA HEALTH CARE PHARMA | GUINEA | $4.2K | 1 |
Biological E. Limited supplies Antitoxin to 18 buyers globally. The largest buyer is WORLD HEALTH ORGANIZATION (UNITED ARAB EMIRATES), followed by MSF LOG-BDX SITE MERIGNAC, (FRANCE) and NCDC NIGERIA CENTRE FOR DISEASE (NIGERIA). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Antitoxin Export Value and How Much Does Biological E. Limited Contribute?
India exported $13.2M worth of Antitoxin through 524 shipments from 45 suppliers to 80 countries, serving 238 buyers globally. Biological E. Limited contributes $1.1M to this total, accounting for 6.0% of India's Antitoxin exports. Biological E. Limited ships Antitoxin to 12 countries through 18 buyers.
What Is the Average Shipment Value for Biological E. Limited's Antitoxin Exports?
Biological E. Limited's average Antitoxin shipment value is $54.9K per consignment, based on 20 shipments totaling $1.1M. The largest destination is UNITED ARAB EMIRATES (33.7% of Biological E. Limited's Antitoxin exports).
How Does Biological E. Limited Compare to Other Indian Antitoxin Exporters?
Biological E. Limited ranks #4 among 45 Indian Antitoxin exporters with a 6.0% market share. The top 3 exporters are VINS BIOPRODUCTS LIMITED ($8.6M), PREMIUM SERUMS AND VACCINES PRIVATE LIMITED ($1.4M), SERUM INSTITUTE OF INDIA PRIVATE LIMITED ($999.9K). Biological E. Limited processed 20 shipments to 10 destination countries.
What Antitoxin Formulations Does Biological E. Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| DIPHTHERIA ANTITOXIN, 10,000 I.U, LYOPHILISED/LIQUID, 10 ML, VIAL | $121.9K | 3 |
| DIPHTHERIA ANTITOXIN 1000/IUML, 10ML VIALS | $100.0K | 2 |
| DIPHTHERIA ANTITOXIN 10 000 I U LYOPHILISED LIQUID 10 ML VIAL | $50.0K | 1 |
| DIPHTHERIA ANTITOXIN 10.000 I.U. LYOPHILISED/ LIQUID 10 ML VIAL | $50.0K | 1 |
| DIPHTHERIA ANTITOXIN, 10,000 I.U, LYOPHILISED/LIQUID, 10 ML, VIALVLS | $50.0K | 1 |
| DIPHTHERIA ANTITOXIN I P 1000 IUML 10ML VIALS DIPHTHERIA ANTITOXIN 10 000 I U 10ML VIAL | $50.0K | 1 |
| DIPHTHERIA ANTITOXIN I.P. 1000/IUML, 10ML VIALS | $27.8K | 1 |
| DIPHTHEREIA ANTITOXIN I.P.1000/IUML10 ML VIALS | $26.2K | 1 |
| TENTANUS ANTITOXIN BP 1500UI ML 1ML | $12.6K | 1 |
| TETANUS ANTITOXIN BP (1500 IU/ML)-1ML AMPOULE (BEATS) | $5.6K | 1 |
Biological E. Limited exports 21 distinct Antitoxin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is DIPHTHERIA ANTITOXIN, 10,000 I.U, LYOPHILISED/LIQUID, 10 ML, with 3 shipments worth $121.9K.
Regulatory Requirements: Exporting Antitoxin to Key Markets
What Biological E. Limited must comply with to export Antitoxin to its top destination countries
Nigeria — NAFDAC
Approval Process
Drug registration under NAFDAC guidelines. WHO-type CPP from India required.
Timeline: 6–18 months
GMP & Export Requirements
WHO GMP compliance; NAFDAC conducts overseas plant inspections
Certificate of Pharmaceutical Product (CPP) from CDSCO India; NAFDAC import permit
Note: India is the largest pharma supplier to Nigeria. NAFDAC has intensified Indian site inspections.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Biological E. Limited Compare to Nearest Antitoxin Exporters?
Exporters ranked immediately above and below #4 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 2 | PREMIUM SERUMS AND VACCINES PRIVATE LIMITED | $1.4M | 71 | 19 | $19.0K |
| 3 | SERUM INSTITUTE OF INDIA PRIVATE LIMITED | $999.9K | 62 | 23 | $16.1K |
| 4 | BIOLOGICAL E. LIMITED ★ | $805.0K | 20 | 10 | $40.2K |
| 5 | VINS BIOPRODUCTS LTD | $373.1K | 19 | 7 | $19.6K |
| 6 | BIOLOGICAL E LIMITED ★ | $293.2K | 6 | 4 | $48.9K |
Biological E. Limited ranks #4 among 45 Indian Antitoxin exporters. Average shipment value of $40.2K compared to the market average of $292.9K. The closest competitors by value are PREMIUM SERUMS AND VACCINES PRIVATE LIMITED and SERUM INSTITUTE OF INDIA PRIVATE LIMITED.
Which Indian Ports Ship Antitoxin Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR CARGO ACC (INBOM4) | 125 | 23.9% |
| HYDERABAD ACC (INHYD4) | 99 | 18.9% |
| HYDERABAD AIR | 87 | 16.6% |
| SAHAR AIR | 74 | 14.1% |
| Bombay Air | 33 | 6.3% |
| Hyderabad Air | 25 | 4.8% |
| HYDERABAD ICD | 12 | 2.3% |
| DELHI AIR | 12 | 2.3% |
What Other Other Products Does Biological E. Limited Export?
Biological E. Limited also exports these other products. Each links to the detailed product page.
Geopolitical & Trade Policy Impact on Biological E. Limited's Antitoxin Exports
The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like BE. The Israel-Iran conflict has disrupted Red Sea shipping routes, leading to increased freight charges and potential losses estimated between ₹2,500 crore and ₹5,000 crore for the Indian pharma industry in March 2026. (fortuneindia.com) These disruptions can elongate lead times and elevate cold-chain failure risks, particularly for temperature-sensitive products like vaccines. (pharmaceuticalcommerce.com)
Conversely, U.S.-China trade tensions have prompted the U.S. to seek alternative suppliers, potentially benefiting Indian exporters. However, the imposition of tariffs on pharmaceutical imports by the U.S. in August 2025 posed challenges, with Indian exporters facing increased costs and competitive disadvantages. (apnews.com) The subsequent withdrawal of tariffs on generic drugs in October 2025 provided some relief, yet the episode underscores the volatility of trade policies and the need for exporters to remain agile. (medboundtimes.com)
In the European Union, compliance with the Falsified Medicines Directive requires stringent serialization and traceability measures. For companies like BE, ensuring adherence to these regulations is crucial to maintain market access and uphold their reputation for quality.
Biological E. Limited — Regulatory Compliance & Quality Standards
Regulatory compliance remains a cornerstone for Indian pharmaceutical exporters. The U.S. FDA has intensified inspections, with over 200 conducted in 2023 and plans to increase this number in 2024. (fact.net.in) Instances of quality issues and FDA warnings have previously affected the reputation of Indian pharma exports. (svhealthcare.in) For BE, maintaining compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP) is imperative to sustain and expand its export footprint.
The company's recent WHO pre-qualification for nOPV2 reflects its commitment to quality and regulatory excellence. However, the broader industry faces challenges related to counterfeit drugs and quality concerns, which can impact India's reputation as a reliable supplier. (fact.net.in) Proactive measures, including robust quality assurance systems and transparent governance, are essential for BE to navigate this evolving landscape.
About Biological E. Limited
Biological E. Limited exports 5 products worth $80.3M. Beyond Antitoxin, top products include Vaccine, Enoxaparin, Sodium, Heparin. View the complete Biological E. Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Antitoxin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Antitoxin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Biological E. Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 26 individual customs records matching Biological E. Limited exporting Antitoxin, covering 21 formulations to 12 countries via 18 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 80+ countries, 238+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Antitoxin Export Data from Biological E. Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Biological E. Limited's Antitoxin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Biological E. Limited
Full Company Profile →
5 products · $80.3M total trade · 3 categories
Antitoxin Stats
Company Overview
Top Products by Biological E. Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Biological E. Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Antitoxin. For current shipment-level data, contact TransData Nexus.